SMMT
HealthcareSummit Therapeutics Inc. · Biotechnology · $13B
What is Summit Therapeutics Inc.?
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious infectious diseases, headquartered in Cambridge, Massachusetts.
Summit Therapeutics discovers and develops antibiotic medicines targeting difficult-to-treat bacterial infections. Its primary focus is Clostridioides difficile infection, a serious gut infection with high recurrence rates. The company generates no commercial revenue yet, funding operations through capital raises while advancing its lead drug candidate through late-stage clinical trials.
The company was founded in 2015 and operates primarily in the United States and Latin America.
- Ridinilazole — oral antibiotic in Phase III trials for C. difficile infection
- SMT-738 — investigational treatment for carbapenem-resistant Enterobacteriaceae
- DDS-04 series — early-stage program targeting Enterobacteriaceae infections
Is SMMT a Good Stock to Buy?
UQS Score rates SMMT as Poor overall, reflecting significant challenges across most evaluated pillars.
The Risk pillar stands out as the relative bright spot in Summit's profile, suggesting the company maintains a manageable near-term financial structure despite its pre-revenue stage.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products and faces an uncertain path to commercialization. Valuation is rated Elevated.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SMMT pay dividends?
No — Summit Therapeutics Inc. does not currently pay a dividend.
Summit Therapeutics does not pay a dividend. As a clinical-stage company with no approved products, available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions.
When does SMMT report earnings?
Summit Therapeutics reports financial results on a quarterly cadence, standard for US-listed companies.
As a pre-revenue biopharmaceutical company, quarterly results center on cash runway, operating expenses, and clinical trial progress rather than sales or profit trends. Pipeline milestones tend to move the stock more than reported financials.
For the most recent quarter's results and updates, visit Summit Therapeutics' investor relations page directly.
SMMT Price History
+237.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Summit Therapeutics Inc.?
Based on Summit Therapeutics Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Summit Therapeutics do?
Summit Therapeutics is a biopharmaceutical company developing antibiotic treatments for serious bacterial infections. Its lead program targets Clostridioides difficile infection, a recurring and difficult-to-treat gut condition. The company is currently in clinical-stage development with no commercially approved products.
Does SMMT pay dividends?
No, SMMT does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors in Summit are generally seeking pipeline-driven appreciation rather than income.
When does SMMT report earnings?
Summit Therapeutics follows a standard quarterly reporting schedule. Because the company has no product revenue, reports focus on cash position and trial updates. Check Summit's investor relations page for the latest schedule.
Is SMMT a good stock to buy?
UQS Score rates SMMT as Poor, with Weak readings across Quality, Moat, and Growth pillars and an Elevated Valuation. The Risk pillar is the lone relative strength. Investors should weigh the high clinical and commercial uncertainty carefully.
Is SMMT overvalued?
The UQS Valuation pillar for SMMT is rated Elevated, suggesting the market is pricing in significant future success relative to the company's current pre-revenue status. Clinical-stage biotechs often carry elevated valuations tied to pipeline potential.
What is SMMT's market cap bracket?
SMMT is classified as a large-cap stock, which is notable for a company still in clinical development. This reflects investor expectations around its pipeline rather than current revenues or earnings.
Is SMMT a long-term quality indicator?
Based on UQS Score's five-pillar framework, SMMT currently scores as Poor, with most pillars rated Weak. Long-term quality typically requires demonstrated profitability, durable competitive advantages, and consistent growth — none of which Summit has established yet.
Who founded Summit Therapeutics?
Summit Therapeutics was founded in 2015. For detailed founding history and leadership background, the company's official website and public filings are the most reliable sources.
Unlock Full SMMT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for SMMT
- ✓Access detailed financial metrics and trend data
- ✓Compare SMMT against sector peers on quality and valuation
- ✓Get the full analyst view available to Pro members
Pro Analysis
SMMT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 14.0 | 0.0 | 11.0 | 0.0 | 74.7 | 0.0 | +4.3 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -4.0 |
| Apr 14, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 72.8 | 0.0 | -9.7 |
| Apr 13, 2026 | 23.4 | 0.0 | 50.0 | 0.0 | 72.8 | 0.0 | +9.7 |
| Apr 2, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 72.8 | 0.0 | — |
SMMT — Pillar Breakdown
Quality
— 0.0/100 (25%)Summit Therapeutics Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Summit Therapeutics Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.7/100 (15%)Summit Therapeutics Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Summit Therapeutics Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Summit Therapeutics Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SMMT.
Score Composition
Financial Data
More Stock Analysis
How is the SMMT UQS Score Calculated?
The UQS (Unified Quality Score) for Summit Therapeutics Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Summit Therapeutics Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Summit Therapeutics Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.